Montana has fewer psychiatrists per capita than nearly any other state in the country — a stark statistic for a state with a substantial mental health burden and a vast, rural geography that makes even a single appointment difficult for many residents to access. For patients in the Livingston area and across the Yellowstone River valley who need ongoing ketamine support between clinical visits, or who may not be candidates for IV infusion as a primary modality, ketamine troches offer a meaningfully different access point. Cassidy Boyer, CRNA, offers ketamine troches at Mend the Mind as a carefully supervised at-home or clinical adjunct treatment — and understands exactly how different they are from IV ketamine and why both have a place in her practice.
How Ketamine Troches Work
Ketamine troches are compounded lozenges that dissolve sublingually — absorbed through the tissues under the tongue rather than swallowed and digested. This delivery route achieves meaningful ketamine plasma levels, though the bioavailability and time course of a troche differs substantially from IV administration. Where IV ketamine produces rapid, predictable, highly controllable plasma levels, troches produce a more gradual onset, lower peak concentrations, and significantly higher inter-individual variability in absorption. Understanding these differences is fundamental to using troches responsibly, and it is why Cassidy Boyer begins every troche patient relationship with a thorough evaluation and a deliberate orientation to what the experience involves and how it differs from IV.
The mechanism through which ketamine troches produce therapeutic effects mirrors that of IV ketamine: blockade of NMDA glutamate receptors, downstream neuroplasticity effects, and — at appropriate doses — a brief altered state of consciousness that can facilitate introspective and therapeutic work. What troches offer that IV administration does not is the possibility of a lower-intensity, home-based experience that some patients find less clinical and more integrated into their therapeutic process. For patients who have already completed an IV ketamine series and have established some neuroplasticity benefit, troches may be used as a maintenance or bridging tool to sustain the progress achieved during infusions. For patients who are not ready for IV or whose symptom profile and life circumstances make monthly office visits the more practical option, troches may serve as a primary treatment modality.
Cassidy Boyer’s Evaluation and Prescribing Standards
At Mend the Mind, ketamine troches are not casually prescribed. Cassidy conducts the same thorough evaluation process for troche patients as for IV infusion candidates — reviewing the patient’s full psychiatric history, prior medication trials, current medications for potential interactions, substance use history, and support structures at home. The question of whether a patient is appropriate for supervised at-home use of a scheduled medication requires careful clinical judgment, and Cassidy approaches that judgment with the same standards she applies to IV administration. Patients who receive troche prescriptions from Mend the Mind receive explicit guidance on dosing, the importance of set and setting, what to expect during the troche experience, and how to approach integration after sessions.
The role of integration is particularly important in the context of ketamine troches. Because the troche experience is often more diffuse and less cinematically intense than IV ketamine, patients sometimes underestimate the degree to which psychological work can occur during or after a session. Cassidy emphasizes that the therapeutic value of troches — like all ketamine-based treatments — is not solely pharmacological. The neuroplasticity window that ketamine opens is an invitation to do psychological work, and patients who engage with that window actively — through journaling, intentional reflection, somatic awareness, or integration sessions with a therapist — typically report richer outcomes than those who experience the altered state passively. This is why Mend the Mind’s troche program is offered within the broader context of Cassidy’s clinical practice rather than as a detached prescription service. To understand more about how ketamine supports neurological healing, see our post on understanding neuroplasticity and ketamine.
Common Misconceptions About Ketamine Troches
One barrier Cassidy encounters frequently with prospective troche patients is the assumption that troches are a “lighter version” of ketamine that don’t require the same degree of clinical oversight. This misunderstanding is dangerous: troches are a Schedule III controlled substance, and the combination of altered consciousness and unsupervised home setting demands a level of preparation and self-awareness that must be cultivated before and during the treatment process. Cassidy addresses this clearly with every patient: troches prescribed through Mend the Mind come with a clinical relationship, ongoing monitoring, and the expectation that the patient will communicate openly about their experiences. They are not a mail-order wellness product. They are a medical treatment that requires appropriate clinical context. Results vary by individual, and Cassidy is direct about what patients should realistically expect.
Not sure whether you’re a good fit for troches or another ketamine modality? Our guide on ketamine therapy candidacy walks through the key criteria Cassidy evaluates.
Access, Telehealth, and Rural Montana Realities
A second barrier is the question of access for patients in remote areas of Montana. The Livingston clinic is Cassidy’s primary treatment location, but she understands that Montana’s geography means some patients are traveling significant distances or need to minimize in-person visits. For established troche patients with a stable treatment history, Cassidy works to balance the clinical necessity of regular check-ins with the practical realities of rural Montana life. Telehealth is incorporated where appropriate for follow-up and integration support. Cassidy uses the Osmind care management platform to maintain clear documentation and communication throughout each patient’s care, and provides superbills for potential insurance reimbursement — because she believes that transparency about cost and access is as important as clinical excellence. Discuss your specific geographic circumstances with Cassidy during your initial consultation.
Frequently Asked Questions
How are ketamine troches different from IV ketamine infusions?
IV ketamine provides rapid, precise, and highly controllable plasma levels and produces a more intense altered state of shorter duration. Troches dissolve sublingually with slower onset, lower peak levels, and greater absorption variability. Both work through the same basic NMDA receptor mechanism but offer different clinical profiles. Cassidy will help you understand which modality — or combination — is best suited to your situation.
Can I use ketamine troches without having done IV ketamine first?
Yes. For some patients, troches are the most appropriate starting point — particularly those who prefer a lower-intensity experience, have logistical constraints around office-based IV sessions, or whose clinical profile suggests troches are a better fit. Cassidy evaluates each patient individually and does not impose a required sequence of modalities.
Where do I take ketamine troches — at home or in the clinic?
Mend the Mind prescribes troches for appropriate patients to use in a supervised at-home setting with specific set and setting guidance, or in the clinical context during an office visit. The setting decision depends on the patient’s history, preparation, and the clinical judgment Cassidy applies during the evaluation process.
What should I do after a troche session to make the most of it?
Integration is a central part of Cassidy’s troche program. After sessions, patients are encouraged to journal, rest, engage in gentle movement, and schedule integration time — either with Cassidy directly or with a therapist they are already working with. Cassidy views the post-session period as therapeutically significant and builds integration support into the treatment relationship.
Are ketamine troches covered by insurance?
Mend the Mind is an out-of-network provider. Cassidy provides superbills after each session for patients to submit to their insurance carriers for potential reimbursement. Coverage varies by plan and diagnosis. Contact our Livingston office to discuss the financial picture for your specific situation.
Key Takeaways
- Ketamine troches are sublingual compounded lozenges with slower onset and greater absorption variability than IV ketamine, acting through the same NMDA receptor mechanism.
- At Mend the Mind, troches are prescribed only after thorough clinical evaluation and are accompanied by explicit preparation and integration guidance.
- Troches can serve as a primary modality, a maintenance bridge after IV infusions, or an adjunct for patients with access constraints.
- Integration — journaling, reflection, and processing — is central to Cassidy’s troche program and significantly affects therapeutic outcomes.
- Results vary by individual; discuss your full history with Cassidy to determine whether troches are appropriate for your situation.
Conclusion
Ketamine troches are a meaningful clinical tool when used with the same rigor and intentionality that Cassidy Boyer applies to every aspect of care at Mend the Mind. For patients in Montana who need flexibility, a lower-intensity ketamine experience, or a maintenance option between IV sessions, troches may be exactly what their treatment has been missing. Schedule a consultation with Mend the Mind in Livingston to learn whether ketamine troches belong in your care plan.
References
National Institutes of Health. Sublingual ketamine pharmacokinetics and bioavailability. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437400/
Multidisciplinary Association for Psychedelic Studies. Integration in psychedelic therapy. https://maps.org/
Drug Enforcement Administration. Schedule III Controlled Substances. https://www.dea.gov/drug-information/drug-scheduling
American Society of Anesthesiologists. Ketamine Clinical Applications. https://www.asahq.org/
About Cassidy Boyer, CRNA
Cassidy Boyer, CRNA, is the lead clinician at Mend The Mind in Livingston, MT, offering IV ketamine therapy and ketamine troches for adults with treatment-resistant depression, anxiety, PTSD, OCD, bipolar disorder, suicidal ideation, and chronic pain conditions including fibromyalgia, neuropathic pain, and restless legs syndrome. Boyer’s evaluation process is built on honest, detailed clinical assessment — reviewing each patient’s full prior treatment history, including medications tried, doses, duration, and response, before making any recommendation. As an out-of-network provider using the Osmind care management platform, Mend The Mind provides patients with superbills for potential insurance reimbursement after each session, combining rigorous clinical standards with direct, transparent communication about what ketamine therapy is and who it is actually appropriate for.
Medical Disclaimer
This content is provided by Mend the Mind for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Ketamine troches are a prescription controlled substance and must only be used under medical supervision with appropriate clinical oversight. Ketamine is used off-label for psychiatric indications. Results vary by individual, and no outcomes are guaranteed. Please discuss all treatment options with your provider before making any decisions about your care.